Dr. Guido Dalbagni, MD

Dr. Dalbagni practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Dalbagni's NPI, 1215916697, was assigned on January 12, 2006. Dr. Dalbagni graduated from Cairo University School of Medicine in 1980. Dr. Dalbagni holds New York license 180605.

Dr. Dalbagni's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Dalbagni's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center (MSK), Department of Surgery. Dmand AI also links Dr. Dalbagni to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dalbagni practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Dalbagni's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Dalbagni is board certified in urology by the American Board of Urology. Dmand AI has Dr. Dalbagni's licenses on file in 2 states: New York and New Jersey.

Dmand AI lists bladder removal, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, prostate cancer, prostate surgery, urinary endoscopy and urinary tract infection among the conditions Dr. Dalbagni treats.

CMS data shows 521 Medicare services from Dr. Dalbagni across 6 procedure codes in 2024, for 425 Medicare patients. Medicare paid $31,023 for them.

CMS counts 425 Medicare patients who saw Dr. Dalbagni in 2024. The largest group is 75 to 84, with 201 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dalbagni's median patient age at 77, with 27% women.

In 2024, Dr. Dalbagni wrote 70 Medicare Part D claims for 33 patients. 99% of them were for generic drugs. CMS names the drug for 30 of them, across 1 drug with 11 or more claims each, at $438 in total drug cost. In 2023, CMS named 54 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Dalbagni for performance year 2024, reported as part of a group.

Dmand AI links 224 papers to Dr. Dalbagni, published from 2003 to 2025. 2020 was the busiest year, with 16. The most frequent topics are Urinary Bladder Neoplasms, Cystectomy and Carcinoma, Transitional Cell. Dr. Dalbagni has published most often in J Urol. Dr. Dalbagni's most frequent co-authors are Bernard H. Bochner, MD, Harry W. Herr, MD and Sherri M. Donat, MD.

Dmand AI links Dr. Dalbagni to 6 clinical trials, 2 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Urinary Bladder Neoplasms, Urinary Bladder Diseases and Non-Muscle Invasive Bladder Neoplasms. Memorial Sloan Kettering Cancer Center sponsors the most, 5.

CMS Open Payments shows 4 general payments to Dr. Dalbagni from 2 drug and device companies from 2016 to 2020. Consulting fees make up the largest share, 98% of the total. Fidia Pharma USA Inc. paid the most, $4,800.

Dmand AI lists 1 award for Dr. Dalbagni.

Dr. Dalbagni graduated from Cairo University School of Medicine in 1980. Dr. Dalbagni is a member of ACS.

Dr. Dalbagni is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.